A White House guest collapsed in the Oval Office on Thursday during President Trump’s announcement on lowering drug prices.
President Trump unveiled new agreements with Eli Lilly and Novo Nordisk to lower weight-loss drug prices.
As Eli Lilly CEO David Ricks was delivering remarks, a man collapsed.
The press was quickly ushered out of the room as Dr. Mehmet Oz and others rushed in to assist the man.
The White House stated that the man who fainted, identified as a guest of Eli Lilly, is okay.
WATCH:
Statement from the White House on new agreements with Eli Lilly and Novo Nordisk:
Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower prescription drug prices, unveiling agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to dramatically reduce the prices Americans pay for some of the world’s most popular drugs.
The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
- The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.
- The price of Zepbound and Orforglipron, if approved, will fall from $1,086 per month to an average of $346 when purchased through TrumpRx.
- In the event that the FDA later approves the Wegovy pill, or certain similar “GLP-1” drugs in each company’s pipeline intended to be taken orally rather than as a shot, the initial dose of those drugs will be priced at $150 per month through TrumpRx.
The historic reduction in prices negotiated by President Trump will enable Medicare and Medicaid to cover obesity drugs for adults at a dramatically lower cost to taxpayers than that proposed by the Biden Administration.
- The Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245, less than half the prices proposed by the Biden Administration on such drugs. State Medicaid programs will also have access to these medications at these prices.
- These low prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time.
- Medicare beneficiaries will pay a co-pay of just $50 per month.
Additionally, the agreement provides for reduced costs on other Eli Lilly and Novo Nordisk medicines when purchased through TrumpRx. For example:
- Eli Lilly will provide Emgality, a treatment for migraines, at $299 per pen, a discount of $443 off of the list price.
- Eli Lilly will provide Trulicity, a commonly used diabetes medicine, at $389 per month, a discount of $598 off of the list price.
- Novo Nordisk will provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month of supply.
The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products.
The post Shocking Moment as Man Collapses in Oval Office During Trump White House Event (VIDEO) appeared first on The Gateway Pundit.